ALTEOGEN Inc. (KOSDAQ:196170)

South Korea flag South Korea · Delayed Price · Currency is KRW
422,000
+16,500 (4.07%)
Aug 22, 2025, 3:30 PM KST
4.07%
Market Cap22.55T
Revenue (ttm)158.06B
Net Income (ttm)94.29B
Shares Out53.44M
EPS (ttm)1,617.35
PE Ratio260.92
Forward PE217.92
Dividendn/a
Ex-Dividend Daten/a
Volume396,656
Average Volume316,583
Open407,000
Previous Close405,500
Day's Range407,000 - 435,500
52-Week Range274,000 - 508,000
Beta1.15
RSI45.35
Earnings DateAug 13, 2025

About ALTEOGEN

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 155
Stock Exchange KOSDAQ
Ticker Symbol 196170
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.